Follicum presents diabetes research at Bio-Europe in Copenhagen

Follicum AB ("Follicum" or the Company") today announces that the Company will present results from their diabetes research during the session ”Is the ecosystem of translational metabolic research in greater Copenhagen sustaining a competitive biotech industry?” November 7. The meeting starts with a panel debate lead by Thomas Landh from Novo Nordisk followed by a  ”Showcase Session” where Follicum will present results from their diabetes research.

Follicum initially identified a new class of peptides that increase insulin secretion in several experimental models. A number of new peptides within this class have been developed to optimize the desirable properties. Several of these induce an improved insulin release which is also potentiated with increasing glucose concentration in in vitro trials. The potential of the peptides as drug candidates has also been confirmed in glucose tolerance tests where they have demonstrated a glucose lowering effect in animal models. In addition, the peptides have been shown to delay the onset of the disease in an animal model for Type I diabetes. These experimental studies have been conducted in collaboration with Follicum's network at Lund University.

The next milestone in the diabetes project is to choose a drug candidate by the beginning of 2019 and advance this candidate towards clinical trials.

About Diabetes
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signaling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as it’s accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications. Follicum's strategy is to drive a well-developed project in the diabetes field that is attractive to global partners.

About Bio-Europe
Bio-Europe is Europe’s largest Life Science partnering conferens with more than 2200 participating companies. The meeting takes place in Copenhagen November 5-7.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB

Telephone: +46 46 19 21 97

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014.


About Us

Follicum AB (publ) develops drug candidates based on tissue reparing peptides with potential use in several therapeutic areas. The company’s primary candidate, FOL-005 for stimulating hair growth, is currently being evaluated in a phase IIa study in collaboration with internationally reputable specialist clinics. The company’s project in diabetes aims at protecting insulin producing cells against damage and thereby reducing the risk of complications. Based on promising preclinical results preparations for entering a phase I study is ongoing, which expects to be initiated in 2021. Both projects have the potential of becoming so called first-in-class drugs. For more information, please visit


Documents & Links